Vaxxa reports increased revenue and a positive result in the fourth quarter of 2025, according to preliminary figures.Revenue amounted to SEK 22.9 million (18.6), corresponding to an increase of 21.9 percent. The Ebitda result came in at SEK 1.07 million (-0.78) and operating profit was SEK 0.61 million (-0.6). The company has moved from development to delivery, writes vd Karl Frindberg. The final year-end report will be published on February 24.